

## press release

### **Novo Nordisk invests DKK 650 million in upgrading and expanding production facilities in Kalundborg**

**Bagsværd, Denmark, 29 March, 2019** – Novo Nordisk today announced plans to invest DKK 650 million in upgrading and expanding facilities at its production site in Kalundborg, Denmark.

The facilities in question are currently manufacturing a range of products for diabetes treatment and will be rebuilt to allow for future production of the next generation of products. The projects are expected to be completed in 2020.

“The investments in production facilities highlight Novo Nordisk’s ambition to continue strengthening its presence in Denmark and Kalundborg. Today, Novo Nordisk manufactures around half of the world’s insulin in Kalundborg and we have had a presence in Kalundborg for 50 years. Since the turn of the millennium alone, Novo Nordisk has invested more than DKK 15 billion in Kalundborg, which is a cornerstone of the company’s global production network”, says Michael Hallgren, SVP for Novo Nordisk production in Kalundborg.

Novo Nordisk and Novozymes are active partners of the Kalundborg Symbiosis, which is a resource partnership between six private companies and three public operators. The main principle of the industrial symbiosis is that a residue or byproduct from one company becomes a resource in another company’s production process. Today, 22 different types of resources are exchanged in the network, resulting in economic and environmental benefits.

Novo Nordisk’s production site in Kalundborg also houses production facilities for Novozymes. Established in 1969, the site today covers a total area of 1,200,000 square metres. Novo Nordisk Kalundborg employs close to 3,500 people, and the 14 factories housed on the site are a cornerstone of Novo Nordisk’s global production network. The site produces 50% of the world’s insulin as well as a range of biopharmaceutical products.

*Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries. For more information, visit [novonordisk.com](http://novonordisk.com), Facebook, Twitter, LinkedIn, YouTube.*

**Further information***Media:*

Mette Kruse Danielsen	+45 3079 3883	<a href="mailto:mkd@novonordisk.com">mkd@novonordisk.com</a>
Ken Inchausti (US)	+1 609 240 9429	<a href="mailto:kiau@novonordisk.com">kiau@novonordisk.com</a>

*Investors:*

Peter Hugrefte Ankersen	+45 3075 9085	<a href="mailto:phak@novonordisk.com">phak@novonordisk.com</a>
Valdemar Borum Svarrer	+45 3079 0301	<a href="mailto:jvls@novonordisk.com">jvls@novonordisk.com</a>
Ann Søndermølle Rendbæk	+45 3075 2253	<a href="mailto:arnd@novonordisk.com">arnd@novonordisk.com</a>
Kristoffer Due Berg (US)	+1 609 235 2989	<a href="mailto:krdb@novonordisk.com">krdb@novonordisk.com</a>